Nonapproved Retatrutide: What 150,000 Social Media Posts Reveal About Side Effects
Retatrutide is one of the most discussed experimental weight-loss drugs in the world, and it is not approved for sale anywhere. Despite that, a growing number of people are buying it online and injecting it. A study published in JAMA Network Open in October 2026 set out to find out what those people say happens to them afterwards.
1. What Is Retatrutide?
Retatrutide is an investigational once-weekly injection that activates three hormone receptors at the same time: GIP, GLP-1, and glucagon. It is the only triple agonist in its class. In a phase 2 obesity trial, participants taking 12 mg per week lost an average of up to 17.5 percent of body weight over 24 weeks, a result that generated enormous public interest. Phase 3 trials are still running, which means no regulator has yet assessed the drug for safety and efficacy.
Because retatrutide is not approved, it cannot be legally sold as a medicine. Products containing it are nevertheless marketed directly to consumers, often labelled “for research use only” or “not for human consumption” to sidestep regulation.
2. How the Study Was Done
Researchers at the University of Pennsylvania collected 148,640 retatrutide-related posts and comments from 38,936 users across 27 Reddit communities focused on retatrutide, peptides, and weight management, covering May 2021 to December 2025. A large language model classified which users described personal use, extracted the symptoms those users attributed to the drug, and mapped each symptom to a Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term.
The team manually validated 100 posts and reported high precision and recall. After excluding weight-loss and appetite-suppression terms, 7,823 users formed the analytic group.
3. The Most Commonly Reported Symptoms
The leading reported terms were not the ones clinicians would expect. The most frequent were:
- Increased appetite – 17.1 percent
- Fatigue – 15.2 percent
- Increased energy – 12.4 percent
- Nausea – 11.6 percent
- Food craving – 7.3 percent
- Insomnia – 6.1 percent
- Increased heart rate – 4.8 percent
Muscle-related complaints such as muscle hypertrophy, myalgia, and muscle atrophy were also notably common, and tachycardia was reported by 3.8 percent of users.
4. How This Differed From Clinical Trial Data
In the phase 2 trial, gastrointestinal events such as nausea, diarrhoea, vomiting, and constipation were the most common adverse events. In the social media data, gastrointestinal symptoms were present but not dominant. Comparing the two datasets descriptively, retatrutide discussion clustered more around appetite, general-system, muscle, sleep, and heart-rate categories, while semaglutide and tirzepatide discussion clustered more around nausea, vomiting, and reduced gut motility.
The authors suggest the difference may relate to retatrutide’s glucagon receptor activity. Glucagon receptor signalling increases energy expenditure, which could plausibly explain reports of increased energy, raised heart rate, and altered appetite. The authors are careful to note that this remains a hypothesis.
5. Why “Increased Appetite” Is the Most Interesting Finding
It sounds contradictory: a drug that produces substantial weight loss, with users reporting that it makes them hungrier. Several explanations are possible, and the study cannot separate them. The product being injected may not be retatrutide at all. The dose may be wrong. Users may be stacking several unapproved peptides at once. The population is unusual, skewing towards bodybuilding and fitness communities. And people who experience a striking symptom are more likely to post about it.
6. What This Study Cannot Tell Us
The authors state plainly that the analysis cannot assess incidence, causality, dose-response, or comparative safety against approved GLP-1 medicines. Product identity, purity, dose, route, treatment duration, and medical history could not be verified for any user. The findings are explicitly described as hypothesis-generating.
In other words, this is a signal, not a verdict. It tells regulators and clinicians where to look. It does not tell anyone what retatrutide does.
7. What Pharmacists and Patients Should Take From It
For health professionals, the practical message is that patients may be using compounds that never appear in their medication record. The authors recommend non-judgemental screening for nonapproved peptide use, counselling about unknown product quality, and reporting suspected adverse events to national pharmacovigilance systems such as MedWatch.
For patients, the message is simpler. A drug sold without approval has no guaranteed identity, no guaranteed dose, and no safety monitoring. Reported experiences on social media are not evidence of what a medicine does, and the people posting are not a representative sample of anyone.
Disclaimer: This article is for informational and educational purposes only. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. Never start, stop, or change a medicine without guidance from your prescriber or pharmacist.
References:
- Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Netw Open. 2026;9(10):e2638929. doi:10.1001/jamanetworkopen.2026.38929
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Nagem Lopes LP, Ramos-Silva A, Gallo de Castro A, Correa de Matos G. Potential utility of social media in pharmacovigilance to identify adverse events and safety signals: a scoping review. Res Social Adm Pharm. 2026;22(5):617-624. doi:10.1016/j.sapharm.2026.02.003
- Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health. 2026;1(8):806-811. doi:10.1038/s44360-026-00108-y
- US Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. FDA.gov. Accessed October 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss




































